Nuplazid
Named-patient access overview. Nuplazid is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Nuplazid (pimavanserin) is a selective 5-HT2A inverse agonist approved by the US Food and Drug Administration in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). The product is marketed approximately by Acadia Pharmaceuticals. Pimavanserin is the first medication FDA-approved specifically for PDP, and its mechanism distinguishes it from typical and atypical antipsychotics that block dopamine receptors and can therefore worsen the motor symptoms of Parkinson's disease. The standard dose is 34 mg once daily.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Nuplazid
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Nuplazid is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Nuplazid in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Nuplazid
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.